Revolutionizing Informed Consent

-

Revolutionizing Informed Consent: Are Multimedia

and eConsent the New Norm?

Informed consent is an essential element of ethical clinical research intended to ensure that participants have a complete comprehension of the nature, risks, and benefits of a trial prior to enrollment. For decades, though, conventional paper-based consent procedures have failed to meet the test. Complex language, inflexible layout, and failure to customize have created barriers for many participants to understand what they are signing, especially in trials with sophisticated medical technologies or heterogeneous, international populations.

Revolutionizing Informed Consent

As clinical trials grow more decentralized, patient-focused, and globally scattered, the shortcomings of traditional methods of obtaining consent have come to the fore. This process, often guided by expert Regulatory Affairs Services in USA  to ensure compliance, has accelerated the emergence of electronic consent (eConsent) and multimedia-supported consent as promising, scalable, and ethically superior solutions.

These formats are not electronic copies of paper versions, they are designed systems intended to improve participant comprehension, boost compliance, and accommodate changing regulatory requirements.

Multimedia and eConsent

eConsent is the application of electronic media to enable the informed consent process, including digital signature capture, interactive documents, and real-time data logging.

Multimedia consent combines audio, video, animation, infographics, and decision aids to communicate trial information more attractively and understandably.


Read the Full blog to know more: https://resource.ddregpharma.com/blogs/revolutionizing-informed-consent-are-multimedia-and-econsent-the-new-norm/

Follow us on :

Facebook: https://www.facebook.com/DDReg/

LinkedIn: https://www.linkedin.com/company/ddregpharma

Twitter: https://x.com/DDRegPharma

Instagram: https://www.instagram.com/ddregpharma

Comments

Post a Comment

Popular posts from this blog

What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development

-
Image
What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development An Investigational Medicinal Product Dossier (IMPD) is a key document in the clinical trial and drug development process, specifically for drugs or biologics undergoing testing in human clinical trials within the European Union (EU). It serves as a comprehensive report detailing the quality, manufacture, and control of the investigational product. The IMPD is a crucial regulatory submission required by the European Medicines Agency (EMA) or national regulatory bodies to evaluate whether a clinical trial can proceed. Key Components of an IMPD The IMPD includes several sections, providing information that ensures the safety and efficacy of the investigational product. These sections typically cover: Product Description and Composition: The IMPD provides detailed information about the investigational product, including its chemical composition, formulation, and dosage forms. Manufacturing and Control: This...
Read more

GMP Compliance in the Era of Advanced Therapies and Biologics

-
Image
Navigating the New Frontier: GMP Compliance for ATMPs and Biologics The global biopharmaceutical industry is undergoing a transformative shift as Advanced Therapy Medicinal Products (ATMPs)—including gene therapies, somatic cell therapies, and tissue-engineered products—and complex biologics become central to innovation pipelines. With over 1,900 active CGT clinical trials globally as of Q2 2025, according to a report by ARM, these living therapies offer unprecedented clinical benefits. However, their unique nature presents a significant challenge: traditional Good Manufacturing Practice (GMP) frameworks, designed for stable, small molecule drugs, are often not directly applicable. Their development, manufacturing, and distribution demand a fundamentally different approach to compliance. often requiring specialized GMP compliance services . The GMP Paradigm Shift for Living Products What makes ATMPs and biologics so unique from a GMP perspective? Living Products with Inherent Variabili...
Read more

Quasi Drugs: Regulatory & Commercial Considerations for Japan and South Korea

-
Image
Navigating Quasi-Drug Regulations and Market Entry in Japan and South Korea In the dynamic Asia-Pacific market, quasi drugs represent a unique regulatory category that bridges the gap between cosmetics and pharmaceuticals . Particularly in Japan and South Korea, quasi drugs have gained traction for their hybrid benefits offering therapeutic claims while maintaining a relatively simpler regulatory pathway compared to full-fledged drugs.    Understanding the regulatory and commercial landscape of quasi drugs in these two key markets is essential for global companies aiming to enter or expand in East Asia. This article explores the updated guidelines, approval requirements, and commercialization opportunities for quasi drugs in Japan and South Korea.  What Are Quasi Drugs? Quasi drugs are defined as products that have mild pharmacological effects or physiological functions. They may not be as potent as traditional drugs, but they go beyond the scope of general cosmetics. Th...
Read more